Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 4Unknown 2Recruiting 2Completed 2Withdrawn 1

Sponsor Class

OTHER 10NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1

Interventions

Paclitaxel 31Cyclophosphamide 30Cisplatin 29Bevacizumab 28Carboplatin 27Fluorouracil 24pembrolizumab 21Nivolumab 21Leucovorin 20Rituximab 19avelumab 18Gemcitabine 18Docetaxel 18Dexamethasone 18Capecitabine 17ALT-803 15130-nm albumin-bound paclitaxel 14Oxaliplatin 12Cetuximab 12fludarabine 11Ipilimumab 11venetoclax 10atezolizumab 10Radiosurgery 10Radiotherapy 9Pemetrexed 9Omacor 9Lenalidomide 9Bendamustine Hydrochloride 9yeast-CEA vaccine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × INDUSTRY × Carmustine × Clear all
NCT00814593 2019-05-10

Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery

Lisata Therapeutics, Inc.

Phase 2 Withdrawn
CNSSarcoma

Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡